

# Frank Schneider

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/362375/publications.pdf>

Version: 2024-02-01

6  
papers

111  
citations

1684188

5  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

107  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SDâ€1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2422-2432.	2.4	30
2	Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEVâ€50717) Compared With Tetrabenazine in Healthy Volunteers. <i>Clinical and Translational Science</i> , 2020, 13, 707-717.	3.1	25
3	Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. <i>Experimental Neurology</i> , 2010, 225, 408-415.	4.1	22
4	Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinsonâ€™s disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor. <i>Journal of Neural Transmission</i> , 2015, 122, 259-272.	2.8	16
5	Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 647-659.	1.6	15
6	The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2021, , 1.	1.9	3